{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:28:25Z","timestamp":1793878105045,"version":"4.7.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1173027"],"award-info":[{"award-number":["GNT1173027"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1173528"],"award-info":[{"award-number":["GNT1173528"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1123673"],"award-info":[{"award-number":["GNT1123673"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2002073"],"award-info":[{"award-number":["GNT2002073"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1149990"],"award-info":[{"award-number":["GNT1149990"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1153493"],"award-info":[{"award-number":["GNT1153493"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["MRF2005544"],"award-info":[{"award-number":["MRF2005544"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","award":["MRF2005544"],"award-info":[{"award-number":["MRF2005544"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41591-021-01377-8","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T06:04:53Z","timestamp":1621231493000},"page":"1205-1211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3861,"title":["Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-1551","authenticated-orcid":false,"given":"David S.","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-5094","authenticated-orcid":false,"given":"Deborah","family":"Cromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-5542","authenticated-orcid":false,"given":"Arnold","family":"Reynaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Schlub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5593-9387","authenticated-orcid":false,"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9072-1017","authenticated-orcid":false,"given":"Jennifer A.","family":"Juno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Subbarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":false,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-2339","authenticated-orcid":false,"given":"James A.","family":"Triccas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1831","authenticated-orcid":false,"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2034545","volume":"384","author":"SF Lumley","year":"2021","unstructured":"Lumley, S. F. et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533\u2013540 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","volume":"27","author":"JH Kim","year":"2021","unstructured":"Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 27, 205\u2013211 (2021).","journal-title":"Nat. Med."},{"key":"1377_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).","journal-title":"Nat. Commun."},{"key":"1377_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639\u2013644 (2021).","journal-title":"Nature"},{"key":"1377_CR5","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8\u2009months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"1377_CR6","doi-asserted-by":"publisher","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature https:\/\/doi.org\/10.1038\/s41586-021-03398-2 (2021).","DOI":"10.1038\/s41586-021-03398-2"},{"key":"1377_CR7","first-page":"767","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70, 767\u2013777 (1972).","journal-title":"J. Hyg."},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2288-10-18","volume":"10","author":"L Coudeville","year":"2010","unstructured":"Coudeville, L. et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methododol. 10, 18 (2010).","journal-title":"BMC Med. Res. Methododol."},{"key":"1377_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","volume":"30","author":"S Black","year":"2011","unstructured":"Black, S. et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30, 1081\u20131085 (2011).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1377_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1128\/CVI.00278-15","volume":"22","author":"KL Laurie","year":"2015","unstructured":"Laurie, K. L. et al. International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE. Clin. Vaccine Immunol. 22, 957\u2013964 (2015).","journal-title":"Clin. Vaccine Immunol."},{"key":"1377_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41577-020-00471-1","volume":"20","author":"DS Khoury","year":"2020","unstructured":"Khoury, D. S. et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat. Rev. Immunol. 20, 727\u2013738 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1377_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"1377_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"1377_CR14","unstructured":"Regeneron Reports Positive Interim Data with REGEN-COV\u2122 Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 (Regeneron press release, 26 January 2021). https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/regeneron-reports-positive-interim-data-regen-covtm-antibody (2021)."},{"key":"1377_CR15","unstructured":"Mattiuzzo, G., et al. Establishment of the WHO International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody (WHO\/BS\/2020\/2403) https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-2020.2403 (WHO, 2020)."},{"key":"1377_CR16","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR17","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR18","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671\u2013681 (2021).","journal-title":"Lancet"},{"key":"1377_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"1377_CR21","doi-asserted-by":"publisher","unstructured":"Sadoff, J. et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2034201 (2021).","DOI":"10.1056\/NEJMoa2034201"},{"key":"1377_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359\u2009years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1377_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR24","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"1377_CR26","unstructured":"Reuters. Sinovac Says COVID-19 Vaccine Effective in Preventing Hospitalization, Death https:\/\/www.reuters.com\/article\/us-health-coronavirus-sinovac-biotech-idUSKBN2A52Q6 (2021)."},{"key":"1377_CR27","unstructured":"Janssen. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial https:\/\/www.janssen.com\/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints (2021)."},{"key":"1377_CR28","unstructured":"Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial (Novavax press release 28 January 2021) https:\/\/ir.novavax.com\/ (2021)."},{"key":"1377_CR29","doi-asserted-by":"publisher","first-page":"n296","DOI":"10.1136\/bmj.n296","volume":"372","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 372, n296 (2021).","journal-title":"BMJ"},{"key":"1377_CR30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1086\/522428","volume":"196","author":"L Qin","year":"2007","unstructured":"Qin, L., Gilbert, P. B., Corey, L., McElrath, M. J. & Self, S. G. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196, 1304\u20131312 (2007).","journal-title":"J. Infect. Dis."},{"key":"1377_CR31","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/sim.2282","volume":"25","author":"AJ Dunning","year":"2006","unstructured":"Dunning, A. J. A model for immunological correlates of protection. Stat. Med. 25, 1485\u20131497 (2006).","journal-title":"Stat. Med."},{"key":"1377_CR32","unstructured":"Bharat Biotech Announces Phase 3 Results of COVAXIN\u00ae: India\u2019s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81% (Bharatbiotech press release 3 March 2021) https:\/\/www.bharatbiotech.com\/press_releases.html (2021)."},{"key":"1377_CR33","doi-asserted-by":"publisher","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00070-0 (2021).","DOI":"10.1016\/S1473-3099(21)00070-0"},{"key":"1377_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","volume":"184","author":"LB Rodda","year":"2021","unstructured":"Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169\u2013183 (2021).","journal-title":"Cell"},{"key":"1377_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.medj.2021.01.005","volume":"2","author":"E Pradenas","year":"2021","unstructured":"Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (NY) 2, 313\u2013320 (2021).","journal-title":"Med"},{"key":"1377_CR37","doi-asserted-by":"publisher","unstructured":"Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe https:\/\/doi.org\/10.1016\/S2666-5247(21)00025-2 (2021).","DOI":"10.1016\/S2666-5247(21)00025-2"},{"key":"1377_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"1377_CR39","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"1377_CR40","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 384, 1468\u20131470 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR41","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384, 1466\u20131468 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR42","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348\u20132361 (2021).","journal-title":"Cell"},{"key":"1377_CR43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"1377_CR44","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012 (2020).","journal-title":"Cell"},{"key":"1377_CR45","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 26, 1428\u20131434 (2020).","journal-title":"Nat. Med."},{"key":"1377_CR46","doi-asserted-by":"publisher","unstructured":"Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-021-00550-x (2021).","DOI":"10.1038\/s41577-021-00550-x"},{"key":"1377_CR47","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR48","doi-asserted-by":"publisher","first-page":"e2006601","DOI":"10.1371\/journal.pbio.2006601","volume":"16","author":"A Antia","year":"2018","unstructured":"Antia, A. et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 16, e2006601 (2018).","journal-title":"PLoS Biol."},{"key":"1377_CR49","unstructured":"Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants. Suite of Guidances Addresses Vaccines, Diagnostics and Therapeutics (FDA news release 22 February 2021) https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus (2021)."},{"key":"1377_CR50","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","volume":"212","author":"AS Monto","year":"2015","unstructured":"Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191\u20131199 (2015).","journal-title":"J. Infect. Dis."},{"key":"1377_CR51","doi-asserted-by":"publisher","first-page":"e00417-16","DOI":"10.1128\/mBio.00417-16","volume":"7","author":"MJ Memoli","year":"2016","unstructured":"Memoli, M. J. et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model. mBio 7, e00417-16 (2016).","journal-title":"mBio"},{"key":"1377_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jviromet.2012.03.004","volume":"182","author":"LW Cheng","year":"2012","unstructured":"Cheng, L. W. et al. Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine. J. Virol. Methods 182, 43\u201349 (2012).","journal-title":"J. Virol. Methods"},{"key":"1377_CR53","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S0950268800048019","volume":"105","author":"KA Callow","year":"1990","unstructured":"Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435\u2013446 (1990).","journal-title":"Epidemiol. Infect."},{"key":"1377_CR54","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/cid\/ciz281","volume":"70","author":"MJ Memoli","year":"2020","unstructured":"Memoli, M. J. et al. Influenza A reinfection in sequential human challenge: implications for protective immunity and \u2018universal\u2019 vaccine development. Clin. Infect. Dis. 70, 748\u2013753 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1377_CR55","first-page":"544","volume":"64","author":"JM Ferdinands","year":"2017","unstructured":"Ferdinands, J. M. et al. Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011\u201312 through 2014\u201315. Clin. Infect. Dis. 64, 544\u2013550 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"1377_CR56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2307\/2335470","volume":"67","author":"J Aitchison","year":"1980","unstructured":"Aitchison, J. & Shen, S. M. Logistic-normal distributions: some properties and uses. Biometrika 67, 261\u2013272 (1980).","journal-title":"Biometrika"},{"key":"1377_CR57","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/2041-210X.12304","volume":"6","author":"K Aho","year":"2015","unstructured":"Aho, K., Bowyer, R. T. & O\u2019Hara, R. B. Confidence intervals for ratios of proportions: implications for selection ratios. Methods Ecol. Evolution 6, 121\u2013132 (2015).","journal-title":"Methods Ecol. Evolution"},{"key":"1377_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00031305.2012.687494","volume":"66","author":"JM Ver Hoef","year":"2012","unstructured":"Ver Hoef, J. M. Who invented the delta method? Am. Statistician 66, 124\u2013127 (2012).","journal-title":"Am. Statistician"},{"key":"1377_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/infdis\/jiaa618","volume":"223","author":"KHD Crawford","year":"2021","unstructured":"Crawford, K. H. D. et al. Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 223, 197\u2013205 (2021).","journal-title":"J. Infect. Dis."},{"key":"1377_CR60","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 383, 1085\u20131087 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1377_CR61","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1198\/jcgs.2009.07130","volume":"18","author":"F Vaida","year":"2009","unstructured":"Vaida, F. & Liu, L. Fast implementation for normal mixed effects models with censored response. J. Comput. Graph. Stat. 18, 797\u2013817 (2009).","journal-title":"J. Comput. Graph. Stat."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-021-01377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-021-01377-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-021-01377-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:04:55Z","timestamp":1684605895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01377-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01377-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.09.21252641","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}